Adalank Research Overview (also known as Adalank peptide, Selank analog, TP-7)
A structurally enhanced derivative of Selank, featuring N-terminal acetylation and C-terminal amidation for superior stability, extended half-life, and improved blood-brain barrier penetration. Studied for anxiety reduction without sedation, cognitive clarity, stress resilience, and mood stabilization.
For broader research context on nootropic compounds, including comparative stacks, cycling considerations, and interaction notes, see the Complete Nootropic Cheat Sheet.
What Is Adalank?
Adalank is a synthetic peptide analog related to the Selank/Semax family of Russian nootropic peptides. It belongs to the class of tuftsin-derived peptides and shares pharmacological properties with Selank, combining anxiolytic, nootropic, and immunomodulatory effects in a single compound.
Mechanism of Action
Adalank exerts its effects through interaction with the enkephalin system and modulation of BDNF expression. It appears to regulate the balance between GABAergic inhibition and glutamatergic excitation in key limbic structures, producing anxiolytic effects without sedation — a profile distinct from benzodiazepines. It also modulates IL-6 and other cytokines, contributing to its anti-inflammatory and immunoregulatory properties.
Research Applications
Research in Russia has examined Adalank for generalized anxiety, mild depression with anxiety features, chronic stress, and cognitive performance under stress conditions. Studies report reduction in anxiety scores, improved working memory, and normalization of stress-related hormonal responses. Like Selank, it is primarily administered intranasally in research settings.
Quick Reference
| Literature-Reported Dose Range | 200-300 mcg |
| Literature-Reported Frequency | 1-2x daily (injectable) or 2-3x daily (nasal) |
| Literature-Reported Cycle Length | 2-4 weeks |
| Literature-Reported Washout | 1-2 weeks minimum |
| Storage | Fridge 2-8°C, use within 14-30 days |
| Sites Reported in Studies | Belly, thigh, arm (SubQ) or nasal spray |
| Timing | Morning preferred, second dose early afternoon if needed |
Research Indications
Anxiety
Generalized Anxiety Disorder (GAD)
Clinical trials with parent compound Selank demonstrated anxiolytic efficacy comparable to benzodiazepines in 62 GAD patients, with 40% showing rapid response within 1-3 days.
Anxiety without Sedation
Unlike benzodiazepines, provides anxiety relief without sedation, amnesia, tolerance, withdrawal, or dependency - critical advantage for long-term management.
Stress-Related Anxiety
Research demonstrates reduction of stress-induced anxiety through modulation of stress hormones and balanced neurotransmitter activity.
Cognitive
Cognitive Enhancement
Demonstrates nootropic and psychostimulant effects alongside anxiolytic properties through BDNF upregulation in hippocampus.
Memory Protection
Protects against memory impairment and attention disturbances through BDNF-mediated neurotrophin mechanisms in hippocampus and prefrontal cortex.
Learning and Attention
Clinical studies show improvements in attention, mental clarity, learning efficiency, and cognitive performance.
Neuroprotective
BDNF Upregulation
Rapidly elevates Brain-Derived Neurotrophic Factor expression in hippocampus, supporting neuroplasticity and long-term cognitive health.
Anti-inflammatory Effects
Research demonstrates significant modulation of 34 inflammation-related genes, providing anti-inflammatory neuroprotection.
Immunomodulation
Derived from tuftsin, provides dual anxiolytic and immunomodulatory therapeutic mechanisms through Th1/Th2 cytokine balance modulation.
Research Protocols
As reported in cited literature and research-community logs (see Research Citations below) — not a personal dosing recommendation.
| Research Application | Dose | Frequency | Route |
|---|
| Anxiety reduction | 200-300mcg | 1-2x daily | SubQ or Nasal |
| Cognitive enhancement | 200-500mcg | 1x daily | SubQ |
| Stress management | 200-300mcg | 2-3x daily | Nasal spray |
| Initial trial | 100-200mcg | 1x daily | SubQ or Nasal |
Timing
Recommended administration window: morning preferred, second dose early afternoon if needed. Typical onset: days for anxiety, 1-2 weeks for cognitive benefits.
Peptide Interactions
Adalank is an enhanced derivative of Selank with improved stability and longer half-life
Both are Russian nootropic peptides with different mechanisms - Semax for cognitive enhancement, Adalank for anxiety
Different mechanisms - Adalank targets neurological/anxiety pathways, BPC-157 focuses on tissue repair
Parent compound Selank enhances benzodiazepine effects while reducing side effects in research studies
Reported Research Timeline
01Days 1–3 (reported in cited studies): 40% may experience rapid anxiety reduction
02Week 1–2 (reported in cited studies): gradual anxiety relief, improved mood and stress resilience
03Week 2–4 (reported in cited studies): cognitive enhancement, improved focus, BDNF-mediated benefits
04Post-treatment: Anxiolytic effects persist for approximately one week
05N-Acetyl form provides extended half-life and enhanced effects vs standard Selank
Safety Notes
Included for harm-reduction awareness only, in the event this compound is encountered outside its labeled research use. Inclusion here does not imply RUO Codes endorses, recommends, or instructs human use.
CRITICAL: Experimental peptide with limited direct research on N-Acetyl form
Parent compound Selank has extensive Russian clinical validation
Approved for clinical use in Russia, not FDA-approved in US
Use sterile technique for injections
No tolerance, dependency, or withdrawal unlike benzodiazepines
Start with lower doses to assess individual response
Cycle with 1-2 week breaks to prevent potential tolerance
Not recommended during pregnancy or breastfeeding
Consult healthcare provider before use
Seek Medical Attention If:
Unusual or persistent headaches
Significant mood changes or depression
Unexpected sedation or extreme fatigue
Unusual neurological symptoms
Persistent injection site reactions or nasal irritation
Any concerning symptoms - consult provider immediately
Quality Indicators
Verified Marker
White, Fluffy Powder
Lyophilized Adalank should appear as white to off-white, fluffy powder filling the vial bottom.
Verified Marker
Clear Solution After Reconstitution
When properly mixed with BAC water, solution should be crystal clear with no particles or cloudiness.
Verified Marker
Proper Labeling
Vial should have clear labeling with peptide name (Adalank or N-Acetyl Selank Amidate), batch number, and storage instructions.
Acceptable Range
Slight Compaction
Minor compaction from shipping is acceptable if powder dissolves completely with gentle swirling.
Quality Concern
Discoloration
Any yellow, brown, or unusual coloration indicates oxidation or degradation. Should be white to off-white only.
Quality Concern
Cloudy After Reconstitution
Persistent cloudiness or particles after mixing indicate degraded or contaminated peptide.
Research Citations
- Efficacy and possible mechanisms of action of a new peptide anxiolytic selank in the therapy of generalized anxiety disorders and neurasthenia
Uchakina, O.N., Uchakin, P.N., Miasoedov, N.F., et al., 2008, Zhurnal Nevrologii i Psikhiatrii imeni SS Korsakova - Selank, Peptide Analogue of Tuftsin, Protects Against Ethanol-Induced Memory Impairment by Regulating of BDNF Content in the Hippocampus and Prefrontal Cortex in Rats
Inozemtsev, A.N., Bokieva, S.B., Karpenko, M.N., et al., 2019, Bulletin of Experimental Biology and Medicine - Peptide Selank Enhances the Effect of Diazepam in Reducing Anxiety in Unpredictable Chronic Mild Stress Conditions in Rats
Kasian, A., Kirbaeva, N., Volodina, M., et al., 2017, Behavioural Neurology - GABA, Selank, and Olanzapine Affect the Expression of Genes Involved in GABAergic Neurotransmission in IMR-32 Cells
Filippenkov, I.B., Stavchansky, V.V., Denisova, A.E., et al., 2017, Frontiers in Pharmacology - The temporary dynamics of inflammation-related genes expression under tuftsin analog Selank action
Sebentsova, E.A., Denisenko, A.V., Levitskaya, N.G., et al., 2013, Immunopharmacology and Immunotoxicology - Expression of inflammation-related genes in mouse spleen under tuftsin analog Selank
Levitskaya, N.G., Sebentsova, E.A., Manchenko, D.M., et al., 2011, Regulatory Peptides - Immunomodulatory effects of selank in patients with anxiety-asthenic disorders
Kolomin, T.A., Agapova, T.Y., Agniullin, Y.V., et al., 2013, Immunopathology, Allergology, Infectology - Optimization of the treatment of anxiety disorders with selank
Kolik, L.G., Nadorova, A.V., Kozlovskaya, M.M., et al., 2015, Zhurnal Nevrologii i Psikhiatrii imeni SS Korsakova
Research Focus
Neuroprotection, Cognitive function, Anxiety reduction, Immunomodulation, Anti-stress
Verified Vendors Carrying Adalank
Frequently Asked Questions
What should researchers watch for with Adalank?
Included for harm-reduction awareness only, in the event this compound is encountered outside its labeled research use. Inclusion here does not imply RUO Codes endorses, recommends, or instructs human use.
What should researchers expect over time with Adalank?
Days 1–3 (reported in cited studies): 40% may experience rapid anxiety reduction
How is Adalank typically administered in research?
As reported in cited literature and research-community logs (see Research Citations below) — not a personal dosing recommendation.
Browse all peptides in the Encyclopedia →